nodes	percent_of_prediction	percent_of_DWPC	metapath
Amisulpride—Metoclopramide—CYP17A1—melanoma	0.0104	1	CrCbGaD
Amisulpride—Deep vein thrombosis—Temozolomide—melanoma	0.0101	0.0229	CcSEcCtD
Amisulpride—Hypokinesia—Carmustine—melanoma	0.0094	0.0214	CcSEcCtD
Amisulpride—Aggression—Bleomycin—melanoma	0.00827	0.0188	CcSEcCtD
Amisulpride—Extrapyramidal disorder—Temozolomide—melanoma	0.00814	0.0185	CcSEcCtD
Amisulpride—Endocrine disorder—Temozolomide—melanoma	0.0074	0.0168	CcSEcCtD
Amisulpride—Breast pain—Temozolomide—melanoma	0.00703	0.016	CcSEcCtD
Amisulpride—Amenorrhoea—Temozolomide—melanoma	0.00698	0.0159	CcSEcCtD
Amisulpride—Weight decreased—Vemurafenib—melanoma	0.00681	0.0155	CcSEcCtD
Amisulpride—Deep vein thrombosis—Docetaxel—melanoma	0.0067	0.0153	CcSEcCtD
Amisulpride—Neuropathy peripheral—Vemurafenib—melanoma	0.00658	0.015	CcSEcCtD
Amisulpride—Pulmonary embolism—Carmustine—melanoma	0.00634	0.0144	CcSEcCtD
Amisulpride—Pulmonary embolism—Temozolomide—melanoma	0.00613	0.014	CcSEcCtD
Amisulpride—Vaginal inflammation—Temozolomide—melanoma	0.00613	0.014	CcSEcCtD
Amisulpride—Vaginal infection—Temozolomide—melanoma	0.00579	0.0132	CcSEcCtD
Amisulpride—Gynaecomastia—Carmustine—melanoma	0.00568	0.0129	CcSEcCtD
Amisulpride—Cardiac disorder—Vemurafenib—melanoma	0.00559	0.0127	CcSEcCtD
Amisulpride—Angiopathy—Vemurafenib—melanoma	0.00547	0.0124	CcSEcCtD
Amisulpride—Malnutrition—Vemurafenib—melanoma	0.00524	0.0119	CcSEcCtD
Amisulpride—HTR2A—hindlimb—melanoma	0.00497	0.116	CbGeAlD
Amisulpride—Amenorrhoea—Docetaxel—melanoma	0.00464	0.0106	CcSEcCtD
Amisulpride—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00443	0.0101	CcSEcCtD
Amisulpride—HTR2A—appendage—melanoma	0.00426	0.0998	CbGeAlD
Amisulpride—Nervous system disorder—Vemurafenib—melanoma	0.0042	0.00955	CcSEcCtD
Amisulpride—Skin disorder—Vemurafenib—melanoma	0.00416	0.00946	CcSEcCtD
Amisulpride—HTR7—endothelium—melanoma	0.00413	0.0966	CbGeAlD
Amisulpride—Weight decreased—Bleomycin—melanoma	0.00412	0.00939	CcSEcCtD
Amisulpride—Pulmonary embolism—Docetaxel—melanoma	0.00408	0.00928	CcSEcCtD
Amisulpride—Hypotension—Vemurafenib—melanoma	0.004	0.0091	CcSEcCtD
Amisulpride—Neutropenia—Dactinomycin—melanoma	0.00398	0.00905	CcSEcCtD
Amisulpride—HTR7—blood vessel—melanoma	0.0038	0.0891	CbGeAlD
Amisulpride—Sweating increased—Temozolomide—melanoma	0.00375	0.00853	CcSEcCtD
Amisulpride—Neutropenia—Carmustine—melanoma	0.00372	0.00847	CcSEcCtD
Amisulpride—Gastrointestinal disorder—Vemurafenib—melanoma	0.00369	0.00841	CcSEcCtD
Amisulpride—Fatigue—Vemurafenib—melanoma	0.00369	0.0084	CcSEcCtD
Amisulpride—Constipation—Vemurafenib—melanoma	0.00366	0.00833	CcSEcCtD
Amisulpride—Neutropenia—Temozolomide—melanoma	0.0036	0.00819	CcSEcCtD
Amisulpride—Hyperglycaemia—Carmustine—melanoma	0.00359	0.00817	CcSEcCtD
Amisulpride—Erectile dysfunction—Temozolomide—melanoma	0.00354	0.00806	CcSEcCtD
Amisulpride—Depression—Carmustine—melanoma	0.00354	0.00805	CcSEcCtD
Amisulpride—Agranulocytosis—Dactinomycin—melanoma	0.00354	0.00805	CcSEcCtD
Amisulpride—Weight increased—Temozolomide—melanoma	0.0035	0.00797	CcSEcCtD
Amisulpride—Weight decreased—Temozolomide—melanoma	0.00348	0.00792	CcSEcCtD
Amisulpride—Neuropathy peripheral—Carmustine—melanoma	0.00348	0.00792	CcSEcCtD
Amisulpride—Hyperglycaemia—Temozolomide—melanoma	0.00347	0.0079	CcSEcCtD
Amisulpride—Depression—Temozolomide—melanoma	0.00342	0.00778	CcSEcCtD
Amisulpride—Neuropathy peripheral—Temozolomide—melanoma	0.00336	0.00765	CcSEcCtD
Amisulpride—Hypersensitivity—Vemurafenib—melanoma	0.00315	0.00718	CcSEcCtD
Amisulpride—Asthenia—Vemurafenib—melanoma	0.00307	0.00699	CcSEcCtD
Amisulpride—Pruritus—Vemurafenib—melanoma	0.00303	0.00689	CcSEcCtD
Amisulpride—Diarrhoea—Vemurafenib—melanoma	0.00293	0.00666	CcSEcCtD
Amisulpride—Cardiac disorder—Temozolomide—melanoma	0.00286	0.0065	CcSEcCtD
Amisulpride—Leukopenia—Bleomycin—melanoma	0.00284	0.00647	CcSEcCtD
Amisulpride—Dizziness—Vemurafenib—melanoma	0.00283	0.00644	CcSEcCtD
Amisulpride—Angiopathy—Temozolomide—melanoma	0.00279	0.00636	CcSEcCtD
Amisulpride—Mental disorder—Carmustine—melanoma	0.00279	0.00635	CcSEcCtD
Amisulpride—Immune system disorder—Temozolomide—melanoma	0.00278	0.00633	CcSEcCtD
Amisulpride—Malnutrition—Carmustine—melanoma	0.00277	0.00631	CcSEcCtD
Amisulpride—HTR7—neck—melanoma	0.00272	0.0637	CbGeAlD
Amisulpride—Vomiting—Vemurafenib—melanoma	0.00272	0.00619	CcSEcCtD
Amisulpride—Orthostatic hypotension—Docetaxel—melanoma	0.0027	0.00615	CcSEcCtD
Amisulpride—Mental disorder—Temozolomide—melanoma	0.0027	0.00614	CcSEcCtD
Amisulpride—Headache—Vemurafenib—melanoma	0.00268	0.0061	CcSEcCtD
Amisulpride—Malnutrition—Temozolomide—melanoma	0.00268	0.0061	CcSEcCtD
Amisulpride—Leukopenia—Dactinomycin—melanoma	0.00265	0.00604	CcSEcCtD
Amisulpride—Tremor—Carmustine—melanoma	0.0026	0.00591	CcSEcCtD
Amisulpride—HTR2A—endothelium—melanoma	0.00257	0.0603	CbGeAlD
Amisulpride—DRD3—head—melanoma	0.00257	0.0602	CbGeAlD
Amisulpride—Agitation—Carmustine—melanoma	0.00255	0.0058	CcSEcCtD
Amisulpride—Nausea—Vemurafenib—melanoma	0.00254	0.00579	CcSEcCtD
Amisulpride—Tremor—Temozolomide—melanoma	0.00251	0.00571	CcSEcCtD
Amisulpride—Leukopenia—Carmustine—melanoma	0.00248	0.00565	CcSEcCtD
Amisulpride—Agitation—Temozolomide—melanoma	0.00246	0.00561	CcSEcCtD
Amisulpride—Angioedema—Temozolomide—melanoma	0.00245	0.00557	CcSEcCtD
Amisulpride—Hypotension—Bleomycin—melanoma	0.00242	0.00551	CcSEcCtD
Amisulpride—Convulsion—Carmustine—melanoma	0.0024	0.00547	CcSEcCtD
Amisulpride—Leukopenia—Temozolomide—melanoma	0.0024	0.00546	CcSEcCtD
Amisulpride—Hypertension—Carmustine—melanoma	0.00239	0.00545	CcSEcCtD
Amisulpride—Neutropenia—Docetaxel—melanoma	0.00239	0.00544	CcSEcCtD
Amisulpride—HTR2A—blood vessel—melanoma	0.00237	0.0556	CbGeAlD
Amisulpride—Anxiety—Carmustine—melanoma	0.00235	0.00535	CcSEcCtD
Amisulpride—Weight increased—Docetaxel—melanoma	0.00233	0.0053	CcSEcCtD
Amisulpride—Convulsion—Temozolomide—melanoma	0.00232	0.00528	CcSEcCtD
Amisulpride—Weight decreased—Docetaxel—melanoma	0.00231	0.00527	CcSEcCtD
Amisulpride—Hypertension—Temozolomide—melanoma	0.00231	0.00527	CcSEcCtD
Amisulpride—Anxiety—Temozolomide—melanoma	0.00227	0.00517	CcSEcCtD
Amisulpride—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00227	0.00516	CcSEcCtD
Amisulpride—Neuropathy peripheral—Docetaxel—melanoma	0.00224	0.00509	CcSEcCtD
Amisulpride—Dry mouth—Temozolomide—melanoma	0.00223	0.00508	CcSEcCtD
Amisulpride—Nervous system disorder—Temozolomide—melanoma	0.00214	0.00488	CcSEcCtD
Amisulpride—Agranulocytosis—Docetaxel—melanoma	0.00213	0.00484	CcSEcCtD
Amisulpride—Skin disorder—Temozolomide—melanoma	0.00212	0.00484	CcSEcCtD
Amisulpride—Hypotension—Carmustine—melanoma	0.00211	0.00481	CcSEcCtD
Amisulpride—Hyperhidrosis—Temozolomide—melanoma	0.00211	0.00481	CcSEcCtD
Amisulpride—Fatigue—Dactinomycin—melanoma	0.00208	0.00475	CcSEcCtD
Amisulpride—Urticaria—Bleomycin—melanoma	0.00206	0.00469	CcSEcCtD
Amisulpride—HTR2B—skin of body—melanoma	0.00206	0.0482	CbGeAlD
Amisulpride—Insomnia—Carmustine—melanoma	0.00205	0.00466	CcSEcCtD
Amisulpride—Somnolence—Carmustine—melanoma	0.00201	0.00458	CcSEcCtD
Amisulpride—Insomnia—Temozolomide—melanoma	0.00198	0.0045	CcSEcCtD
Amisulpride—Gastrointestinal pain—Dactinomycin—melanoma	0.00198	0.0045	CcSEcCtD
Amisulpride—Gastrointestinal disorder—Carmustine—melanoma	0.00195	0.00445	CcSEcCtD
Amisulpride—Somnolence—Temozolomide—melanoma	0.00194	0.00443	CcSEcCtD
Amisulpride—Constipation—Carmustine—melanoma	0.00194	0.00441	CcSEcCtD
Amisulpride—Dyspepsia—Temozolomide—melanoma	0.00193	0.00438	CcSEcCtD
Amisulpride—DRD2—eye—melanoma	0.00191	0.0448	CbGeAlD
Amisulpride—Abdominal pain—Dactinomycin—melanoma	0.00191	0.00435	CcSEcCtD
Amisulpride—Hypersensitivity—Bleomycin—melanoma	0.00191	0.00435	CcSEcCtD
Amisulpride—Cardiac disorder—Docetaxel—melanoma	0.0019	0.00432	CcSEcCtD
Amisulpride—DRD2—retina—melanoma	0.0019	0.0444	CbGeAlD
Amisulpride—Gastrointestinal disorder—Temozolomide—melanoma	0.00189	0.0043	CcSEcCtD
Amisulpride—Fatigue—Temozolomide—melanoma	0.00189	0.00429	CcSEcCtD
Amisulpride—Constipation—Temozolomide—melanoma	0.00187	0.00426	CcSEcCtD
Amisulpride—Asthenia—Bleomycin—melanoma	0.00186	0.00423	CcSEcCtD
Amisulpride—Angiopathy—Docetaxel—melanoma	0.00186	0.00423	CcSEcCtD
Amisulpride—Gastrointestinal pain—Carmustine—melanoma	0.00185	0.00421	CcSEcCtD
Amisulpride—Immune system disorder—Docetaxel—melanoma	0.00185	0.00421	CcSEcCtD
Amisulpride—Pruritus—Bleomycin—melanoma	0.00183	0.00418	CcSEcCtD
Amisulpride—Mental disorder—Docetaxel—melanoma	0.00179	0.00408	CcSEcCtD
Amisulpride—Abdominal pain—Carmustine—melanoma	0.00179	0.00407	CcSEcCtD
Amisulpride—Gastrointestinal pain—Temozolomide—melanoma	0.00179	0.00407	CcSEcCtD
Amisulpride—Malnutrition—Docetaxel—melanoma	0.00178	0.00406	CcSEcCtD
Amisulpride—Hypersensitivity—Dactinomycin—melanoma	0.00178	0.00406	CcSEcCtD
Amisulpride—Urticaria—Temozolomide—melanoma	0.00174	0.00395	CcSEcCtD
Amisulpride—Asthenia—Dactinomycin—melanoma	0.00173	0.00395	CcSEcCtD
Amisulpride—Abdominal pain—Temozolomide—melanoma	0.00173	0.00394	CcSEcCtD
Amisulpride—Muscle spasms—Docetaxel—melanoma	0.00171	0.0039	CcSEcCtD
Amisulpride—HTR2A—neck—melanoma	0.0017	0.0397	CbGeAlD
Amisulpride—Hypersensitivity—Carmustine—melanoma	0.00167	0.0038	CcSEcCtD
Amisulpride—Diarrhoea—Dactinomycin—melanoma	0.00165	0.00377	CcSEcCtD
Amisulpride—Vomiting—Bleomycin—melanoma	0.00165	0.00375	CcSEcCtD
Amisulpride—Asthenia—Carmustine—melanoma	0.00162	0.0037	CcSEcCtD
Amisulpride—Hypersensitivity—Temozolomide—melanoma	0.00161	0.00367	CcSEcCtD
Amisulpride—Leukopenia—Docetaxel—melanoma	0.0016	0.00363	CcSEcCtD
Amisulpride—Asthenia—Temozolomide—melanoma	0.00157	0.00357	CcSEcCtD
Amisulpride—Diarrhoea—Carmustine—melanoma	0.00155	0.00352	CcSEcCtD
Amisulpride—Pruritus—Temozolomide—melanoma	0.00155	0.00352	CcSEcCtD
Amisulpride—Convulsion—Docetaxel—melanoma	0.00154	0.00351	CcSEcCtD
Amisulpride—Nausea—Bleomycin—melanoma	0.00154	0.00351	CcSEcCtD
Amisulpride—Hypertension—Docetaxel—melanoma	0.00154	0.0035	CcSEcCtD
Amisulpride—Vomiting—Dactinomycin—melanoma	0.00154	0.0035	CcSEcCtD
Amisulpride—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00151	0.00343	CcSEcCtD
Amisulpride—Dizziness—Carmustine—melanoma	0.0015	0.00341	CcSEcCtD
Amisulpride—Diarrhoea—Temozolomide—melanoma	0.0015	0.00341	CcSEcCtD
Amisulpride—Dry mouth—Docetaxel—melanoma	0.00148	0.00338	CcSEcCtD
Amisulpride—Dizziness—Temozolomide—melanoma	0.00145	0.00329	CcSEcCtD
Amisulpride—Vomiting—Carmustine—melanoma	0.00144	0.00328	CcSEcCtD
Amisulpride—Nausea—Dactinomycin—melanoma	0.00144	0.00327	CcSEcCtD
Amisulpride—Nervous system disorder—Docetaxel—melanoma	0.00143	0.00325	CcSEcCtD
Amisulpride—Headache—Carmustine—melanoma	0.00142	0.00323	CcSEcCtD
Amisulpride—Skin disorder—Docetaxel—melanoma	0.00141	0.00322	CcSEcCtD
Amisulpride—Vomiting—Temozolomide—melanoma	0.00139	0.00317	CcSEcCtD
Amisulpride—Headache—Temozolomide—melanoma	0.00137	0.00312	CcSEcCtD
Amisulpride—Hypotension—Docetaxel—melanoma	0.00136	0.00309	CcSEcCtD
Amisulpride—Nausea—Carmustine—melanoma	0.00134	0.00306	CcSEcCtD
Amisulpride—HTR2B—head—melanoma	0.00134	0.0314	CbGeAlD
Amisulpride—Insomnia—Docetaxel—melanoma	0.00132	0.00299	CcSEcCtD
Amisulpride—Nausea—Temozolomide—melanoma	0.0013	0.00296	CcSEcCtD
Amisulpride—Somnolence—Docetaxel—melanoma	0.00129	0.00294	CcSEcCtD
Amisulpride—Dyspepsia—Docetaxel—melanoma	0.00128	0.00291	CcSEcCtD
Amisulpride—HTR2A—eye—melanoma	0.00126	0.0296	CbGeAlD
Amisulpride—Gastrointestinal disorder—Docetaxel—melanoma	0.00126	0.00286	CcSEcCtD
Amisulpride—Fatigue—Docetaxel—melanoma	0.00125	0.00285	CcSEcCtD
Amisulpride—HTR2A—retina—melanoma	0.00125	0.0293	CbGeAlD
Amisulpride—Constipation—Docetaxel—melanoma	0.00124	0.00283	CcSEcCtD
Amisulpride—Gastrointestinal pain—Docetaxel—melanoma	0.00119	0.00271	CcSEcCtD
Amisulpride—Abdominal pain—Docetaxel—melanoma	0.00115	0.00262	CcSEcCtD
Amisulpride—HTR7—head—melanoma	0.00115	0.0269	CbGeAlD
Amisulpride—DRD2—head—melanoma	0.00109	0.0254	CbGeAlD
Amisulpride—Hypersensitivity—Docetaxel—melanoma	0.00107	0.00244	CcSEcCtD
Amisulpride—Asthenia—Docetaxel—melanoma	0.00104	0.00238	CcSEcCtD
Amisulpride—Pruritus—Docetaxel—melanoma	0.00103	0.00234	CcSEcCtD
Amisulpride—Diarrhoea—Docetaxel—melanoma	0.000995	0.00227	CcSEcCtD
Amisulpride—Dizziness—Docetaxel—melanoma	0.000962	0.00219	CcSEcCtD
Amisulpride—HTR2B—lymph node—melanoma	0.00094	0.022	CbGeAlD
Amisulpride—Vomiting—Docetaxel—melanoma	0.000925	0.0021	CcSEcCtD
Amisulpride—Headache—Docetaxel—melanoma	0.000911	0.00207	CcSEcCtD
Amisulpride—Nausea—Docetaxel—melanoma	0.000864	0.00197	CcSEcCtD
Amisulpride—HTR2A—head—melanoma	0.000717	0.0168	CbGeAlD
Amisulpride—DRD2—Signaling Pathways—CSF2—melanoma	7.64e-05	0.000151	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—FGF1—melanoma	7.64e-05	0.000151	CbGpPWpGaD
Amisulpride—HTR7—Signaling by GPCR—KRAS—melanoma	7.59e-05	0.00015	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—BRAF—melanoma	7.57e-05	0.000149	CbGpPWpGaD
Amisulpride—DRD2—GPCR downstream signaling—IL2—melanoma	7.53e-05	0.000148	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—CSF2—melanoma	7.52e-05	0.000148	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—FGF1—melanoma	7.52e-05	0.000148	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—CD80—melanoma	7.51e-05	0.000148	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—KIT—melanoma	7.5e-05	0.000148	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—PIK3CG—melanoma	7.5e-05	0.000148	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—APC—melanoma	7.5e-05	0.000148	CbGpPWpGaD
Amisulpride—DRD3—Signaling by GPCR—NRAS—melanoma	7.5e-05	0.000148	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—E2F1—melanoma	7.48e-05	0.000147	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—PIK3CB—melanoma	7.44e-05	0.000147	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—FGF2—melanoma	7.42e-05	0.000146	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—EGF—melanoma	7.41e-05	0.000146	CbGpPWpGaD
Amisulpride—HTR2A—GPCR downstream signaling—IL2—melanoma	7.4e-05	0.000146	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—PDGFRA—melanoma	7.4e-05	0.000146	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—IGF1—melanoma	7.38e-05	0.000145	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—E2F1—melanoma	7.36e-05	0.000145	CbGpPWpGaD
Amisulpride—HTR2B—Signaling by GPCR—MAPK1—melanoma	7.34e-05	0.000145	CbGpPWpGaD
Amisulpride—HTR2B—Signaling by GPCR—EGFR—melanoma	7.34e-05	0.000145	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—PRKCA—melanoma	7.32e-05	0.000144	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—ITGB3—melanoma	7.32e-05	0.000144	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—PIK3CB—melanoma	7.32e-05	0.000144	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—PDGFRA—melanoma	7.28e-05	0.000143	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—ITGB3—melanoma	7.21e-05	0.000142	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—PRKCA—melanoma	7.21e-05	0.000142	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—SPP1—melanoma	7.18e-05	0.000142	CbGpPWpGaD
Amisulpride—DRD3—Signaling by GPCR—MAPK3—melanoma	7.18e-05	0.000141	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—MAP2K2—melanoma	7.16e-05	0.000141	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—CXCL8—melanoma	7.15e-05	0.000141	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—MAP2K1—melanoma	7.13e-05	0.00014	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—PIK3CD—melanoma	7.08e-05	0.00014	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—SPP1—melanoma	7.07e-05	0.000139	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—BRAF—melanoma	7.05e-05	0.000139	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—MAP2K2—melanoma	7.04e-05	0.000139	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—CXCL8—melanoma	7.04e-05	0.000139	CbGpPWpGaD
Amisulpride—HTR2B—GPCR downstream signaling—PIK3CA—melanoma	7.02e-05	0.000138	CbGpPWpGaD
Amisulpride—HTR7—Signaling by GPCR—PIK3CA—melanoma	6.97e-05	0.000137	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—MDM2—melanoma	6.94e-05	0.000137	CbGpPWpGaD
Amisulpride—HTR2B—Signaling by GPCR—KRAS—melanoma	6.93e-05	0.000137	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—IGF1—melanoma	6.86e-05	0.000135	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—ERBB2—melanoma	6.85e-05	0.000135	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—IL2—melanoma	6.83e-05	0.000135	CbGpPWpGaD
Amisulpride—DRD3—Signaling by GPCR—MAPK1—melanoma	6.83e-05	0.000135	CbGpPWpGaD
Amisulpride—DRD3—Signaling by GPCR—EGFR—melanoma	6.83e-05	0.000135	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—TERT—melanoma	6.81e-05	0.000134	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—RAC1—melanoma	6.79e-05	0.000134	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—FGF2—melanoma	6.78e-05	0.000134	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—PIK3CB—melanoma	6.76e-05	0.000133	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—IL2—melanoma	6.72e-05	0.000132	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—TERT—melanoma	6.7e-05	0.000132	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—RAC1—melanoma	6.68e-05	0.000132	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—MAP2K1—melanoma	6.63e-05	0.000131	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—PIK3CD—melanoma	6.59e-05	0.00013	CbGpPWpGaD
Amisulpride—DRD3—GPCR downstream signaling—PIK3CA—melanoma	6.53e-05	0.000129	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—HIF1A—melanoma	6.51e-05	0.000128	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—CXCL8—melanoma	6.49e-05	0.000128	CbGpPWpGaD
Amisulpride—DRD3—Signaling by GPCR—KRAS—melanoma	6.45e-05	0.000127	CbGpPWpGaD
Amisulpride—HTR7—Signaling by GPCR—HRAS—melanoma	6.45e-05	0.000127	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—HIF1A—melanoma	6.41e-05	0.000126	CbGpPWpGaD
Amisulpride—HTR2B—Signaling by GPCR—PIK3CA—melanoma	6.37e-05	0.000126	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—MDM2—melanoma	6.35e-05	0.000125	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—CDKN1B—melanoma	6.34e-05	0.000125	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—FGF2—melanoma	6.31e-05	0.000124	CbGpPWpGaD
Amisulpride—HTR7—GPCR downstream signaling—AKT1—melanoma	6.27e-05	0.000124	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—ERBB2—melanoma	6.26e-05	0.000123	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—KDR—melanoma	6.23e-05	0.000123	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—CASP3—melanoma	6.21e-05	0.000122	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—IL2—melanoma	6.2e-05	0.000122	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—PIK3CB—melanoma	6.17e-05	0.000122	CbGpPWpGaD
Amisulpride—HTR7—Signaling by GPCR—IL6—melanoma	6.17e-05	0.000122	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—KDR—melanoma	6.13e-05	0.000121	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—CCND1—melanoma	6.05e-05	0.000119	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—FN1—melanoma	5.99e-05	0.000118	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—CTNNB1—melanoma	5.99e-05	0.000118	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—CXCL8—melanoma	5.93e-05	0.000117	CbGpPWpGaD
Amisulpride—DRD3—Signaling by GPCR—PIK3CA—melanoma	5.93e-05	0.000117	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—MDM2—melanoma	5.9e-05	0.000116	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—FN1—melanoma	5.9e-05	0.000116	CbGpPWpGaD
Amisulpride—HTR2B—Signaling by GPCR—HRAS—melanoma	5.89e-05	0.000116	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—MMP9—melanoma	5.87e-05	0.000116	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—NOTCH1—melanoma	5.87e-05	0.000116	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—CDKN1A—melanoma	5.85e-05	0.000115	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—PTEN—melanoma	5.84e-05	0.000115	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—ERBB2—melanoma	5.82e-05	0.000115	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—NFKB1—melanoma	5.81e-05	0.000114	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—CDKN1B—melanoma	5.79e-05	0.000114	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—NOTCH1—melanoma	5.77e-05	0.000114	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—CD80—melanoma	5.75e-05	0.000113	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—PIK3CB—melanoma	5.74e-05	0.000113	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—APC—melanoma	5.74e-05	0.000113	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—KIT—melanoma	5.74e-05	0.000113	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—PIK3CG—melanoma	5.74e-05	0.000113	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—NRAS—melanoma	5.74e-05	0.000113	CbGpPWpGaD
Amisulpride—HTR2B—GPCR downstream signaling—AKT1—melanoma	5.73e-05	0.000113	CbGpPWpGaD
Amisulpride—HTR7—Signaling by GPCR—AKT1—melanoma	5.7e-05	0.000112	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—CASP3—melanoma	5.68e-05	0.000112	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—EGF—melanoma	5.67e-05	0.000112	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—IL2—melanoma	5.67e-05	0.000112	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—CD80—melanoma	5.65e-05	0.000111	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—KIT—melanoma	5.64e-05	0.000111	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—PIK3CG—melanoma	5.64e-05	0.000111	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—APC—melanoma	5.64e-05	0.000111	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—NRAS—melanoma	5.64e-05	0.000111	CbGpPWpGaD
Amisulpride—HTR2B—Signaling by GPCR—IL6—melanoma	5.64e-05	0.000111	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—EGF—melanoma	5.58e-05	0.00011	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—CCND1—melanoma	5.53e-05	0.000109	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—CXCL8—melanoma	5.52e-05	0.000109	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—MAPK3—melanoma	5.49e-05	0.000108	CbGpPWpGaD
Amisulpride—DRD3—Signaling by GPCR—HRAS—melanoma	5.48e-05	0.000108	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—CTNNB1—melanoma	5.47e-05	0.000108	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—MAPK3—melanoma	5.41e-05	0.000107	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—BRAF—melanoma	5.39e-05	0.000106	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—CDKN1B—melanoma	5.39e-05	0.000106	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—MMP9—melanoma	5.37e-05	0.000106	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—CDKN1A—melanoma	5.35e-05	0.000105	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—PTEN—melanoma	5.33e-05	0.000105	CbGpPWpGaD
Amisulpride—DRD3—GPCR downstream signaling—AKT1—melanoma	5.33e-05	0.000105	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—NFKB1—melanoma	5.31e-05	0.000105	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—BRAF—melanoma	5.31e-05	0.000105	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—CASP3—melanoma	5.28e-05	0.000104	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—IL2—melanoma	5.28e-05	0.000104	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—VEGFA—melanoma	5.27e-05	0.000104	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—IGF1—melanoma	5.25e-05	0.000103	CbGpPWpGaD
Amisulpride—DRD3—Signaling by GPCR—IL6—melanoma	5.25e-05	0.000103	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—MAPK1—melanoma	5.23e-05	0.000103	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—EGFR—melanoma	5.23e-05	0.000103	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—STAT3—melanoma	5.22e-05	0.000103	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—NRAS—melanoma	5.21e-05	0.000103	CbGpPWpGaD
Amisulpride—HTR2B—Signaling by GPCR—AKT1—melanoma	5.2e-05	0.000103	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—IGF1—melanoma	5.17e-05	0.000102	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—MAPK1—melanoma	5.14e-05	0.000101	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—CCND1—melanoma	5.14e-05	0.000101	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—EGFR—melanoma	5.14e-05	0.000101	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—CTNNB1—melanoma	5.09e-05	0.0001	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—MAP2K1—melanoma	5.08e-05	0.0001	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—PIK3CD—melanoma	5.04e-05	9.94e-05	CbGpPWpGaD
Amisulpride—DRD2—GPCR downstream signaling—PIK3CA—melanoma	5e-05	9.84e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—MAP2K1—melanoma	4.99e-05	9.84e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—MMP9—melanoma	4.99e-05	9.84e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—MAPK3—melanoma	4.99e-05	9.83e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—CDKN1A—melanoma	4.98e-05	9.8e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—PTEN—melanoma	4.96e-05	9.78e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—PIK3CD—melanoma	4.96e-05	9.78e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—NFKB1—melanoma	4.94e-05	9.73e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—KRAS—melanoma	4.94e-05	9.73e-05	CbGpPWpGaD
Amisulpride—HTR2A—GPCR downstream signaling—PIK3CA—melanoma	4.91e-05	9.68e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—KRAS—melanoma	4.86e-05	9.57e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—MYC—melanoma	4.85e-05	9.56e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling by GPCR—AKT1—melanoma	4.84e-05	9.54e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—FGF2—melanoma	4.83e-05	9.51e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—VEGFA—melanoma	4.82e-05	9.49e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—STAT3—melanoma	4.77e-05	9.4e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—NRAS—melanoma	4.76e-05	9.38e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—FGF2—melanoma	4.75e-05	9.36e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—MAPK1—melanoma	4.75e-05	9.35e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—EGFR—melanoma	4.75e-05	9.35e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—MAPK3—melanoma	4.56e-05	8.98e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—PIK3CA—melanoma	4.54e-05	8.94e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—MDM2—melanoma	4.52e-05	8.9e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—VEGFA—melanoma	4.48e-05	8.83e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—KRAS—melanoma	4.48e-05	8.83e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—PIK3CA—melanoma	4.46e-05	8.79e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—ERBB2—melanoma	4.45e-05	8.78e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—MDM2—melanoma	4.45e-05	8.76e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—STAT3—melanoma	4.44e-05	8.75e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—MYC—melanoma	4.43e-05	8.73e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—NRAS—melanoma	4.43e-05	8.73e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—PIK3CB—melanoma	4.4e-05	8.66e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—ERBB2—melanoma	4.38e-05	8.63e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—MAPK1—melanoma	4.34e-05	8.54e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—EGFR—melanoma	4.34e-05	8.54e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—PIK3CB—melanoma	4.33e-05	8.52e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—MAPK3—melanoma	4.24e-05	8.36e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—CXCL8—melanoma	4.22e-05	8.32e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—HRAS—melanoma	4.2e-05	8.27e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—CXCL8—melanoma	4.16e-05	8.19e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—HRAS—melanoma	4.13e-05	8.14e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—CDKN1B—melanoma	4.13e-05	8.13e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—MYC—melanoma	4.13e-05	8.13e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—PIK3CA—melanoma	4.12e-05	8.11e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—KRAS—melanoma	4.1e-05	8.07e-05	CbGpPWpGaD
Amisulpride—DRD2—GPCR downstream signaling—AKT1—melanoma	4.08e-05	8.04e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—CDKN1B—melanoma	4.06e-05	8e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—CASP3—melanoma	4.04e-05	7.97e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—IL2—melanoma	4.04e-05	7.95e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—MAPK1—melanoma	4.04e-05	7.95e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—EGFR—melanoma	4.03e-05	7.95e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—IL6—melanoma	4.02e-05	7.91e-05	CbGpPWpGaD
Amisulpride—HTR2A—GPCR downstream signaling—AKT1—melanoma	4.02e-05	7.91e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—TP53—melanoma	3.98e-05	7.85e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—CASP3—melanoma	3.98e-05	7.84e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—IL2—melanoma	3.97e-05	7.83e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—IL6—melanoma	3.95e-05	7.79e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—CCND1—melanoma	3.94e-05	7.75e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—CTNNB1—melanoma	3.9e-05	7.68e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—CCND1—melanoma	3.87e-05	7.63e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—CTNNB1—melanoma	3.83e-05	7.55e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—MMP9—melanoma	3.82e-05	7.53e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—KRAS—melanoma	3.81e-05	7.51e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—HRAS—melanoma	3.81e-05	7.51e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—CDKN1A—melanoma	3.81e-05	7.5e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—PTEN—melanoma	3.8e-05	7.48e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—NFKB1—melanoma	3.78e-05	7.45e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—PIK3CA—melanoma	3.76e-05	7.41e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—MMP9—melanoma	3.76e-05	7.41e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—CDKN1A—melanoma	3.75e-05	7.38e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—PTEN—melanoma	3.74e-05	7.36e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—NFKB1—melanoma	3.72e-05	7.33e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling by GPCR—AKT1—melanoma	3.71e-05	7.3e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—IL6—melanoma	3.65e-05	7.18e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling by GPCR—AKT1—melanoma	3.65e-05	7.18e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—TP53—melanoma	3.64e-05	7.17e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—PIK3CA—melanoma	3.5e-05	6.9e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—HRAS—melanoma	3.48e-05	6.86e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—VEGFA—melanoma	3.43e-05	6.76e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—STAT3—melanoma	3.4e-05	6.69e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—NRAS—melanoma	3.39e-05	6.68e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—TP53—melanoma	3.39e-05	6.67e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—VEGFA—melanoma	3.38e-05	6.65e-05	CbGpPWpGaD
Amisulpride—HTR7—Signaling Pathways—AKT1—melanoma	3.36e-05	6.63e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—STAT3—melanoma	3.34e-05	6.59e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—NRAS—melanoma	3.33e-05	6.57e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—IL6—melanoma	3.33e-05	6.57e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—MAPK3—melanoma	3.25e-05	6.39e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—HRAS—melanoma	3.24e-05	6.38e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—MAPK3—melanoma	3.19e-05	6.29e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—MYC—melanoma	3.16e-05	6.22e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—MYC—melanoma	3.11e-05	6.12e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—IL6—melanoma	3.1e-05	6.11e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—MAPK1—melanoma	3.09e-05	6.08e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—EGFR—melanoma	3.09e-05	6.08e-05	CbGpPWpGaD
Amisulpride—HTR2B—Signaling Pathways—AKT1—melanoma	3.07e-05	6.06e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—MAPK1—melanoma	3.04e-05	5.99e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—EGFR—melanoma	3.04e-05	5.99e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—KRAS—melanoma	2.92e-05	5.75e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—KRAS—melanoma	2.87e-05	5.65e-05	CbGpPWpGaD
Amisulpride—DRD3—Signaling Pathways—AKT1—melanoma	2.86e-05	5.64e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—PIK3CA—melanoma	2.68e-05	5.28e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—PIK3CA—melanoma	2.64e-05	5.19e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—TP53—melanoma	2.59e-05	5.11e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—TP53—melanoma	2.55e-05	5.03e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—HRAS—melanoma	2.48e-05	4.88e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—HRAS—melanoma	2.44e-05	4.81e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—IL6—melanoma	2.37e-05	4.67e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—IL6—melanoma	2.33e-05	4.6e-05	CbGpPWpGaD
Amisulpride—DRD2—Signaling Pathways—AKT1—melanoma	2.19e-05	4.31e-05	CbGpPWpGaD
Amisulpride—HTR2A—Signaling Pathways—AKT1—melanoma	2.15e-05	4.24e-05	CbGpPWpGaD
